Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 · kind B2 · utility
17Cited by
50References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 2003 |
| Grant date | Jul 3, 2007 |
| Priority date | — |
| Expiry date | Apr 21, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.